View Item 

Show simple item record

Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics
dc.contributor.authorRoberts, J. Scotten_US
dc.contributor.authorChristensen, Kurt D.en_US
dc.contributor.authorGreen, Robert C.en_US
dc.date.accessioned2011-11-10T15:31:28Z
dc.date.available2013-01-02T16:31:57Zen_US
dc.date.issued2011-11en_US
dc.identifier.citationRoberts, JS; Christensen, KD; Green, RC (2011). "Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics." Clinical Genetics 80(5). <http://hdl.handle.net/2027.42/86823>en_US
dc.identifier.issn0009-9163en_US
dc.identifier.issn1399-0004en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86823
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherAlzheimer Diseaseen_US
dc.subject.otherAPOEen_US
dc.subject.otherGenetic Testingen_US
dc.subject.otherRisk Communicationen_US
dc.titleUsing Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomicsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeneticsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86823/1/j.1399-0004.2011.01739.x.pdf
dc.identifier.doi10.1111/j.1399-0004.2011.01739.xen_US
dc.identifier.sourceClinical Geneticsen_US
dc.identifier.citedreferenceBurke W, Psaty BM. Personalized medicine in the era of genomics. JAMA 2007: 298: 1682 – 1684.en_US
dc.identifier.citedreferenceUrquidi V, Goodison S. Genomic signatures of breast cancer metastasis. Cytogenet Genome Res 2007: 118: 116 – 129.en_US
dc.identifier.citedreferenceHudson K, Javitt G, Burke W et al. ASHG statement on direct‐to‐consumer genetic testing in the United States. Am J Hum Genet 2007: 81: 635 – 637.en_US
dc.identifier.citedreferenceOffit K. Genomic profiles for disease risk: predictive or premature? JAMA 2008: 299: 1353 – 1355.en_US
dc.identifier.citedreferenceBurke W. Clinical validity and clinical utility of genetic tests. Curr Protoc Hum Genet 2009: 60: 9.15.11 – 19.15.17.en_US
dc.identifier.citedreferenceHubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med 1996: 334: 1192 – 1193.en_US
dc.identifier.citedreferenceEvans JP. Health care in the age of genetic medicine. JAMA 2007: 298: 2670 – 2672.en_US
dc.identifier.citedreferenceSecretary's Advisory Committee on Genetics, Health and Society. A roadmap for the integration of genetics and genomics into health and society. Washington, DC: Department of Health & Human Services, 2004.en_US
dc.identifier.citedreferenceCollins FS, Green ED, Guttmacher AE et al. A vision for the future of genomics research. Nature 2003: 422: 835 – 847.en_US
dc.identifier.citedreferenceGo VLW, Wong DA, Wang Y et al. Diet and cancer prevention: evidence‐based medicine to genomic medicine. J Nutr 2004: 134: 3513S – 3516S.en_US
dc.identifier.citedreferenceAlzheimer's Association 2011. Alzheimer's disease facts and figures. Alzheimers Dement 2011: 7: 208 – 244.en_US
dc.identifier.citedreferenceSteinbart EJ, Smith CO, Poorkaj P et al. Impact of DNA testing for early‐onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001: 58: 1828 – 1831.en_US
dc.identifier.citedreferenceMihaescu R, Detmar SB, Cornel MC et al. Translational research in genomics of Alzheimer's disease: a review of current practice and future perspectives. J Alzheimers Dis 2010: 20: 967 – 980.en_US
dc.identifier.citedreferenceBertram L, Lange C, Mullin K et al. Genome‐wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008: 83: 623 – 632.en_US
dc.identifier.citedreferenceHollingworth P, Harold D, Sims R et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011: 43: 429 – 435.en_US
dc.identifier.citedreferenceFarrer LA, Brin MF, Elsas L et al. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995: 274: 1627 – 1629.en_US
dc.identifier.citedreferenceRelkin NR, Gandy S. Consensus statements on the use of ApoE genotyping in Alzheimer's Disease. Neurol Alert 1996: 14: 58 – 59.en_US
dc.identifier.citedreferencePost SG, Whitehouse PJ, Binstock RH et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 1997: 277: 832 – 836.en_US
dc.identifier.citedreferenceMcConnell LM, Koenig BA, Greely HT et al. Genetic testing and Alzheimer disease: has the time come? Nat Med 1998: 4: 757 – 759.en_US
dc.identifier.citedreferenceMorris JC. Dementia update 2005. Alzheimer Dis Assoc Disord 2005: 19: 100 – 117.en_US
dc.identifier.citedreferenceRoberts JS, Connell CM. Illness representations among first‐degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 2000: 14: 129 – 136.en_US
dc.identifier.citedreferenceChristensen KD, Roberts JS, Uhlmann WR et al. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 2011: 13: 409 – 414.en_US
dc.identifier.citedreferenceLautenschlager NT, Cupples LA, Rao VS et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 1996: 46: 641 – 650.en_US
dc.identifier.citedreferenceFarrer LA, Cupples LA, Blackburn S et al. Interrater agreement for diagnosis of Alzheimer's disease: the MIRAGE study. Neurology 1994: 44: 652 – 656.en_US
dc.identifier.citedreferenceFarrer LA, Cupples LA, Haines JL et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta‐analysis. JAMA 1997: 278: 1349 – 1356.en_US
dc.identifier.citedreferenceWashington HA. Medical apartheid: the dark history of medical experimentation on Black Americans from colonial times to the present. New York, NY: Doubleday, 2006.en_US
dc.identifier.citedreferenceChristensen KD, Roberts JS, Royal CDM et al. Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL Study experience. Genet Med 2008: 10: 207 – 214.en_US
dc.identifier.citedreferenceRoberts JS, Barber M, Brown TM et al. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 2004: 6: 197 – 203.en_US
dc.identifier.citedreferenceEsplen MJ, Madlensky L, Aronson M et al. Colorectal cancer survivors undergoing genetic testing for hereditary non‐polyposis colorectal cancer: motivational factors and psychosocial functioning. Clin Genet 2007: 72: 394 – 401.en_US
dc.identifier.citedreferenceHensley Alford S, McBride CM, Reid RJ et al. Participation in genetic testing research varies by social group. Public Health Genomics 2011: 14: 85 – 93.en_US
dc.identifier.citedreferenceRoberts JS, LaRusse SA, Katzen H et al. Reasons for seeking genetic susceptibility testing among first‐degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 2003: 17: 86 – 93.en_US
dc.identifier.citedreferenceWoloshin S, Schwartz LM. How can we help people make sense of medical data? Eff Clin Pract 1999: 2: 176 – 183.en_US
dc.identifier.citedreferenceLipkus IM. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making 2007: 27: 696 – 713.en_US
dc.identifier.citedreferenceRoberts JS, Cupples LA, Relkin NR et al. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study. J Geriatr Psychiatry Neurol 2005: 18: 250 – 255.en_US
dc.identifier.citedreferenceEckert SL, Katzen H, Roberts JS et al. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genet Med 2006: 8: 746 – 751.en_US
dc.identifier.citedreferenceLaRusse S, Roberts JS, Marteau TM et al. Genetic susceptibility testing versus family history‐based risk assessment: impact on perceived risk of Alzheimer disease. Genet Med 2005: 7: 48 – 53.en_US
dc.identifier.citedreferenceLinnenbringer E, Roberts JS, Hiraki S et al. “I know what you told me, but this is what I think:” perceived risk of Alzheimer disease among individuals who accurately recall their genetics‐based risk estimate. Genet Med 2010: 12: 219 – 227.en_US
dc.identifier.citedreferenceBeck AT, Epstein N, Brown G et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988: 56: 893 – 897.en_US
dc.identifier.citedreferenceRadloff LS. The CES‐D scale: a self‐report depression scale for research in the general population. Appl Psychol Meas 1977: 1: 385 – 401.en_US
dc.identifier.citedreferenceHorowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979: 41: 209 – 218.en_US
dc.identifier.citedreferenceGreen RC, Roberts JS, Cupples LA et al. A randomized trial of APOE genotype disclosure for risk of Alzheimer's disease: the REVEAL Study. N Engl J Med 2009: 361: 245 – 254.en_US
dc.identifier.citedreferenceHeshka JT, Palleschi C, Howley H et al. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008: 10: 19 – 32.en_US
dc.identifier.citedreferenceMeiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 2005: 14: 1060 – 1074.en_US
dc.identifier.citedreferenceMarteau TM, Lerman C. Genetic risk and behavioural change. BMJ 2001: 322: 1056 – 1059.en_US
dc.identifier.citedreferenceMarteau T, Senior V, Humphries SE et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A 2004: 128A: 285 – 293.en_US
dc.identifier.citedreferencePhelan JC, Yang LH, Cruz‐Rojas R. Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. Psychiatr Serv 2006: 57: 382 – 387.en_US
dc.identifier.citedreferenceSenior V, Marteau TM. Causal attributions for raised cholesterol and perceptions of effective risk‐reduction: self‐regulation strategies for an increased risk of coronary heart disease. Psychol Health 2007: 22: 699 – 717.en_US
dc.identifier.citedreferenceChao S, Roberts JS, Marteau TM et al. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord 2008: 22: 94 – 97.en_US
dc.identifier.citedreferenceZick CD, Mathews CJ, Roberts JS et al. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff 2005: 24: 483 – 490.en_US
dc.identifier.citedreferenceTaylor DH Jr, Cook‐Deegan RM, Hiraki S et al. Genetic testing for Alzheimer's and long‐term care insurance. Health Aff 2010: 29: 102 – 108.en_US
dc.identifier.citedreferenceBinetti G, Benussi L, Roberts S et al. Areas of intervention for genetic counselling of dementia: cross‐cultural comparison between Italians and Americans. Patient Educ Couns 2006: 64: 285 – 293.en_US
dc.identifier.citedreferenceResta RG. Defining and redefining the scope and goals of genetic counseling. Am J Med Genet 2006: 142: 269 – 275.en_US
dc.identifier.citedreferenceGuttmacher AE. Human genetics on the web. Annu Rev Genomics Hum Genet 2001: 2: 213 – 233.en_US
dc.identifier.citedreferenceGuttmacher AE, Jenkins J, Uhlmann WR. Genomic medicine: who will practice it? A call to open arms. Am J Med Genet 2001: 106: 216 – 222.en_US
dc.identifier.citedreferenceGreen RC, Roberts JS, Chen C et al. Comparing the impact of a condensed vs extended protocol for disclosure of APOE to relatives of patients with AD: The REVEAL Study. Alzheimers Dement 2007: 3: S184.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-0004.2011.01739.x.pdf
Size:
587.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.